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Prolonged isolated thrombocytopenia (PT) is a serious complication after allogeneic hematopoietic stem
cell transplantation (allo-HSCT). However, it remains unclear whether abnormalities of the bone marrow
(BM) microenvironment are involved in the pathogenesis of PT. This prospective, nested case-control study
included 20 patients with PT, 40 matched patients with good graft function (GGF) after allo-HSCT, and 16
healthy donors (HDs). Cellular elements of the BM microenvironment, including BM endothelial cells
(BMECs), perivascular cells, and endosteal cells, were analyzed via ﬂow cytometry and via hematoxylin-
eosin and immunohistochemical staining in situ. Moreover, stromal-derived factor 1 (SDF-1) and
vascular endothelial growth factor (VEGF) were measured in the plasma of BM via an enzyme-linked
immunosorbent assay. No signiﬁcant differences in endosteal cells (15 per high-power ﬁeld [hpf] versus
16 per hpf versus 20 per hpf, P > .05) were demonstrated among the patients with PT, GGF, and the HDs. The
PT patients exhibited remarkable decreases in cellular elements of the vascular microenvironment,
including BMECs (.01% versus .18% versus .20%, P < .0001) and perivascular cells (.01% versus .12% versus
.13%, P < .0001), compared with the GGF allo-HSCT recipients and the HDs, respectively. Moreover,
signiﬁcantly lower levels of SDF-1 (3163 pg/mL versus 3928 pg/mL, P ¼ .0002) and VEGF (56 pg/mL versus
123 pg/mL, P < .0001) were found in the BM plasma of the PT patients compared with the BM of the GGF
patients. A multivariate analysis revealed that BMECs (odds ratio [OR] ¼ 171.57, P ¼ .002) and cytomega-
lovirus infection after HSCT (OR ¼ 4.35, P ¼ .009) were independent risk factors for PT. Our data suggested
that an impaired BM vascular microenvironment and megakaryocyte-active factors may contribute to the
occurrence of PT after HSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Prolonged isolated thrombocytopenia (PT), which is deﬁned
as the engraftment of all peripheral blood cell lines other than
a platelet (PLT) count  20  109/L or dependence on PLT
transfusions for more than 90 days after allogeneic hemato-
poietic stem cell transplantation (allo-HSCT) [1,2], remains a
serious complication after allo-HSCT. Several risk factors,
including the source of the stem cells, the doses of infused
CD34þ cells, disease status, graft-versus-host disease (GVHD),
and cytomegalovirus (CMV) infection, have been proposed to
be associated with PT after allo-HSCT [3-6]. However, the
underlying mechanisms remain to be elucidated.
Emerging evidence from mouse studies has suggested
that effective hematopoiesis depends on a particular bone
marrow (BM) microenvironment in which hematopoietic
stem cells (HSCs) reside [7,8]. BM endothelial cells
(BMECs), endosteal cells, and perivascular cells have beenedgments on page 1196.
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14.04.015identiﬁed as key supporting elements for HSCs in the
murine BM microenvironment [9-11]. We recently estab-
lished a reliable assay for the anatomic and phenotypic
detection of the human equivalents of the above-described
murine BM microenvironment elements [12]. Moreover,
the frequency of the aforementioned elements has been
demonstrated to be remarkably reduced in patients with
secondary poor graft function (PGF) compared with pa-
tients with good graft function (GGF) and healthy donors
(HDs), indicating that the impairment of the BM microen-
vironment contributes to the occurrence of secondary PGF
after HSCT [12].
In mice, the cross-talk between megakaryocytes (MKs)
and BMECs in the BM vascular microenvironment regulates
MKs maturation and thrombopoiesis [13,14]. Therefore, we
hypothesized that an impaired BM microenvironment may
hamper MKs maturation, possibly translating to the occur-
rence of PT after HSCT. To conﬁrm our hypothesis, a pro-
spective, nested case-control study was conducted to
evaluate whether the levels of the above-described compo-
nents of the BM microenvironment [12] and MK-active fac-
tors [14] in allo-HSCT patients with PT differed from those in
patients with GGF or in HDs. Our aim was to provide new
insights into the pathogenesis underlying PT after allo-HSCT.Transplantation.
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Patients and Controls
A prospective, nested case-control study was designed. Cases were
identiﬁed from a cohort of 418 patients who underwent allo-HSCT for
hematologic malignancies between October 1, 2012 and September 30,
2013 at the Peking University Institute of Hematology. A total of 20 patients
who had developed PT after allo-HSCT were eligible for inclusion. For each
case, 2 matched controls with GGF (n ¼ 40) were randomly selected from
the same cohort of patients undergoing treatment at the time that PT
occurred in the cases. Using a risk set sampling design [15], the controls
were matched according to the following criteria: age at HSCT (1 years),
pre-HSCT cycles of chemotherapy (1 cycle), disease status at HSCT, and
the duration between HSCT and the evaluation of the BM microenviron-
ment (5 days). The characteristics of the PT cases and controls are sum-
marized in Table 1.
BM samples from 16 HDs were used as healthy control specimens. The
HDs consisted of 8 males and 8 females, and their ages ranged from 18 to
50 years (median, 27 years). The study was approved by the ethics com-
mittee of Peking University People’s Hospital, and written informed consent
was obtained from all the subjects before study entry, in accordance with
the Declaration of Helsinki.
Clinical Deﬁnitions and Evaluation
Hematopoietic engraftment after transplantation was deﬁned as the
reconstitution of both neutrophil and PLT numbers. Neutrophil reconstitu-
tion was deﬁned as occurring during the ﬁrst 3 consecutive days with an
absolute neutrophil count (ANC) > .5  109/L, and PLT reconstitution was
deﬁned as the ﬁrst time that PLT levels reached > 20  109/L for 7
consecutive days.
GGFwas deﬁned as persistent successful engraftment (ANC > .5  109/L
for 3 consecutive days, PLT counts > 20  109/L for 7 consecutive days, and
hemoglobin [Hb] levels >70 g/L without transfusion support) beyond
28 days after HSCT [12]. PT was deﬁned as the engraftment of all peripheral
blood cell lines other than a PLT count  20  109/L or dependence on PLT
transfusions for more than 90 days after allo-HSCT [1,2] in the presence of
complete donor chimerism. Patients with evidence of PGF [12] or hemato-
logic relapse within 90 days after transplantation were excluded.
Chimerism analyses were performed using DNA ﬁngerprinting for short
tandem repeats in blood samples and/or ﬂuorescence in situ chromosomal
hybridization in BM samples. Full donor chimerismwas deﬁned as the failure
to detect recipient hematopoietic or lymphoid cells using either of the above
methods. The underlying diseases were further categorized as standard-risk
or high-risk. Standard-risk patients were deﬁned as patients in the ﬁrst or
second complete remission of acute leukemia, patients in the ﬁrst chronic
phase of chronic myelocytic leukemia, or patients with myelodysplastic
syndrome. All other patients were classiﬁed as high-risk. Hematologic
relapsewas deﬁned as the reappearance of blasts in the blood, BM (>5%) or
any extramedullary site after complete remission and was determined using
commonmorphological criteria. GVHDwas scored as acute or chronic based
on published criteria [16,17].
Transplantation Protocols
Donor selection, HLA typing, stem cell harvesting, conditioning therapy,
and GVHD prophylaxis were conducted as previously described [12,18-21].
The grafts that were transplanted were both rh granulocyte colonye-
stimulating factoremobilized peripheral blood stem cells and BM stem cells
from HLA-matched or HLA-mismatched sibling donors.
All allo-HSCT patients were screened for CMV serostatus before trans-
plantation. Weekly real-time quantitative PCR for the detection of CMV DNA
was performed to detect CMV reactivation in the blood after allo-HSCT. CMV
infections were treated with ganciclovir or foscarnet, as previously
described [22].
Immunophenotypic Analysis of Cellular Components in the BM
Microenvironment
As previously reported [12,23,24], the BMECs and perivascular cells in
the PT patients, GGF patients, and HDs were analyzed using ﬂow cytometry.
In brief, 5 mL of fresh BM was stained with mouse antihuman CD45, CD34,
CD146, and vascular endothelial growth factor receptor 2 (VEGFR2) mono-
clonal antibodies (BD Biosciences, San Jose, CA), and staining was detected
using a FACSCalibur (BD Biosciences).
Histological Analysis of the BM Microenvironment
Bone marrow trephine biopsies (BMB) were obtained from 20 PT pa-
tients, 40 matched GGF patients, and 16 HDs. H & E staining and immuno-
histochemistry (IHC) with rabbit antihuman osteopontin, CD34, and CD146(Abcam, Cambridge, MA) were performed on each BMB section obtained
from the patients and controls, as previously described [12]. Each section
was examined using light microscopy (Axiovert 200; Carl Zeiss, Jena,
Germany).Methods of Assessment in Histological Analysis
BMB cellularity was assessed via visual examination and categorized
into 3 groups [25]. MKs were identiﬁed as large cells with blue/gray cyto-
plasm, which often contained large, multilobed nuclei. MKs were quantiﬁed
as the number per high-power ﬁeld (hpf), and endosteal cells were quan-
tiﬁed as the number of osteopontin-positive cells on the line of the
trabecular bone per hpf. The number of CD146-positive perivascular cells
per microvessel was counted. The BM microvessel density in BMB sections
was enumerated using IHC with a CD34-reactive monoclonal antibody, ac-
cording to Perez-Atayde et al. [26]. The median number of vessels per
trabecular bone was recorded. The data from the routinely stained H & E
sections were compared with the information obtained from IHC. The
enumerations were performed by 2 blinded observers.Enzyme-linked Immunosorbent Assay (ELISA) to Detect Megakaryocyte-
active Factors
The levels of stromal-derived factor 1 (SDF-1) and vascular endothelial
growth factor (VEGF) in the BM plasma samples from PT and GGF patients
were quantiﬁed using a Quantikine Human Immunoassay kit (R&D Systems,
Minneapolis, MN; and Abcam, Cambridge, MA) according to the manufac-
turer’s protocol. BM plasma samples from HDs were used as a normal
control. Brieﬂy, EDTA-anticoagulated BM was centrifuged at 1000 g for
15 minutes within 30 minutes of collection. An additional centrifugation
step of the separated plasma at 10,000 g for 10 minutes at 4C was per-
formed to obtain platelet-poor plasma, which was then aliquoted and stored
at 80C until testing. All the samples were analyzed in duplicate. The
absorbance was measured using a Model 680 microplate reader (Bio-Rad,
Berkeley, CA). The personnel who performed the ELISA assays were blinded
to the clinical background of the samples.Statistical Analysis
The characteristics of the patients in the PT and GGF groups were
compared using the chi-square test for categorical variables and the Mann-
Whitney U test for continuous variables. The statistical analyses were per-
formed using a 1-way analysis of variance (ANOVA) to compare the 3 groups.
Factors with P < .10, as determined via a univariate logistic analysis, were
included in the multivariate logistic regression analysis. Factors with P < .05
were considered to be independently associated with the occurrence of PT.
All statistical procedures were performed using the SPSS 16.0 (IBM, Armonk,
NY) and GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA) software
packages, and P < .05 was considered statistically signiﬁcant.RESULTS
Patient Characteristics
Twenty patients with PT and 40 matched patients with
GGF after allo-HSCT were enrolled in this study. To minimize
the potential inﬂuence of the length of time since allo-HSCT,
the BM microenvironments of the PT and GGF patients were
evaluated at similar median times after allo-HSCT (95 days
versus 93 days, P> .05). Moreover, PCR DNA ﬁngerprinting of
the short tandem repeats of the recipient BM cells was used
to conﬁrm 100% donor chimerism in these patients.
As shown in Table 1, there were no signiﬁcant differences
between the allo-HSCT patients with PT and those with GGF
(P > .05) in demographic and clinical characteristics, in-
cluding age, gender, underlying disease, disease status before
transplantation, median time from diagnosis to trans-
plantation, source of stem cells, transplanted total nucleated
cell dose, CD34þ cell dose, donor HLA match, sex/ABO
mismatch, pre-HSCT chemotherapy cycles, conditioning,
history of GVHD, and duration of anti-CMV therapy. How-
ever, a larger proportion of PT patients had a history of CMV
infection shortly after allo-HSCT compared with the GGF
patients (P ¼ .02).
Table 1
Characteristics of Allo-HSCT Patients with PT and GGF
Characteristics PT Cases* (n ¼ 20) GGF Cases* (n ¼ 40) P Valuey
BM evaluated time (post-HSCT), median (range), d 95 (90-150) 93 (90-148) .79
BMB cellularity, median (range), % 35 (25-40) 45 (30-50) <.0001
Megakaryocytes, median (range), % per hpf 2 (0-3) 5 (3-7) <.0001
BM microenvironment elements
BMECs, median (range), % .01 (.001-.12) .18 (.08-.25) <.0001
CD146þ perivascular cells, median (range), % .01 (.002-.06) .12 (.06-.20) <.0001
Osteopontinþ endosteal cells, median (range), % per hpf 15 (10-19) 16 (10-20) .10
CD34þ microvessels (per trabecular bone), median (range) 2 (0-3) 4 (2-7) <.0001
Blood cell count
WBC, median (range), 109/L 2.66 (1.36-6.84) 3.88 (1.99-6.17) .001
ANC, median (range), 109/L 1.90 (.71-5.82) 2.92 (.89-5.23) .002
Hb, median (range), g/L 86.52 (74-110) 104 (76-122) <.0001
PLT, median (range), 109/L 13.51 (9-19) 112.50 (45-223) <.0001
Age at HSCT, median (range), yr 37.50 (18-57) 38.50 (20-56) .89
Gender (male/female), n 11/9 22/18 1.00
Underlying disease
AML, n 7 21 .27
ALL, n 8 15 1.00
MDS, n 5 4 .15
Status at HSCT .15
Standard risk, n 9 10
High risk, n 11 30
Source of stem cell 1.00
BM and PB 20 40
Transplanted total nucleated cell dose, median (range),  108/kg 7.35 (3.68-9.70) 7.10 (3.50-10.08) .67
Transplanted CD34þ cells, median (range),  106/kg 2.49 (1.99-3.52) 2.41 (1.23-3.37) .25
Donor match 1.00
HLA-identical sibling donor, n 5 9
HLA-partially matched related donor, n 15 31
Sex mismatch
Female to male, n 4 6 .72
Female to female, n 4 4 .42
Male to female, n 7 12 .77
Male to male, n 5 18 .17
ABO mismatch
No, n 10 20 1.00
Minor, n 5 9 1.00
Major, n 5 11 1.00
Pre-HSCT cycles of chemotherapy 4 (0-7) 5 (0-10) .08
Conditioning 1.00
BU/CY, n 5 9
BU/CY þ ATG, n 15 31
History of GVHD, n 14 16 .05
History of CMV reactivation, n 17 22 .02
Duration of anti CMV therapy, median (range), d 21 (15-52) 22 (17-55) .80
Allo-HSCT indicates allogeneic hematopoietic stem cell transplantation; PT, prolonged isolated thrombocytopenia; GGF, good graft function; BM, bone marrow;
BMB, bone marrow trephine biopsies; hpf, high-power ﬁeld; BMECs, bone marrow endothelial cells; ANC, absolute neutrophil cell; Hb, hemoglobin; PLT,
platelet; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; MDS, myelodysplastic syndrome; PB, peripheral blood; BU, busulfan; CY,
cyclophosphamide; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; CMV, cytomegalovirus.
* Group matching criteria included age at HSCT (1 years), pre-HSCT cycles of chemotherapy (1 cycle), disease status at HSCT and BM microenvionment
evaluated time after HSCT (5 days). For each case, 2 GGF controls were randomly selected from the same cohort at which the PT occurred (“risk-set sampling”).
y The continuous variables were compared using the Mann-Whitney U-test, and the differences in frequency between the 2 groups were compared using the
chi-square test. The criterion for statistical signiﬁcance was P < .05.
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Although white blood cells (WBC) and hemoglobin (Hb)
were successfully engrafted when the BMwas evaluated, the
PT patients exhibited signiﬁcantly reduced hemogramvalues
compared with the GGF controls. When the BM microenvi-
ronment was evaluated, the median WBC (2.66  109/L
versus 3.88  109/L, P ¼ .001), ANC (1.90  109/L versus
2.92  109/L, P ¼ .002), Hb (86.52 g/L versus 104 g/L,
P < .0001), and PLT (13.51  109/L versus 112.50  109/L,
P < .0001) levels in the PT group were dramatically lower
compared with the GGF group (Table 1).
As illustrated in Figure 1, the BMB cellularity (35% versus
45%, P< .0001) andMKs numbers (2 per hpf versus 5 per hpf,P < .0001) were signiﬁcantly decreased in the PT group
compared with the GGF group.
Quantiﬁcation of CD34þ Cells, BMECs, and Perivascular
Cells in BM using Flow Cytometry
As demonstrated in Figure 2, the median number of
CD34þ cells in the BM mononuclear cells (BMMNCs) was
signiﬁcantly decreased in the PT group compared with the
GGF group (4.16  106/mL versus 6.83  106/mL, P ¼ .03),
although no signiﬁcant difference in the percentage of
CD34þ cells in the BMMNCs was observed between the PT
and GGF patients when the BM was evaluated (.25% versus
.26%, P > .05).
Figure 1. The cellularity of BMB (A1-A3) and megakaryocytes (B1-B3) in the PT group was signiﬁcantly reduced compared with the GGF and HD groups. Original
magniﬁcation 10 times for BMB. Original magniﬁcation 40 times for megakaryocytes. Red arrows indicate megakaryocytes.
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perivascular cells were analyzed using ﬂow cytometry, ac-
cording to previously reported gating strategies [12,23,24].Figure 2. Although there were no signiﬁcant differences in the transplanted CD34þ
BMECs (C), and perivascular cells (D) in the BM of the allo-HSCT recipients with PT w
Statistical analyses were performed using 1-way ANOVA. BMECs indicates bone marAs shown in Figure 2, the frequency of BMECs (.01% versus
.18% versus .20%, P < .0001) and perivascular cells (.01%
versus .12% versus .13%, P < .0001) in the BMMNCs werecell dose between the PT and GGF groups (A), the number of CD34þ cells (B),
ere signiﬁcantly reduced compared with those of the GGF patients and HDs.
row endothelial cells; BMMNCs, bone marrow mononuclear cells.
Figure 3. In situ expression of a vascular microenvironment marker by bone marrow endothelial cells in human BMB. The microvessel density was signiﬁcantly
reduced in the PT patients compared with the GGF patients and HDs according to the results of H & E (A1-A3) and IHC staining with CD34 (B1-B3). Original
magniﬁcation 40 times. Red arrows indicate microvessels.
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GGF patients and HDs.Histological Analysis of BMECs, Perivascular Cells, and
Endosteal Cells
In situ histological analyses of the BMB were performed
to further characterize the human BM microenvironment
elements in patients after allo-HSCT. Consistent with our
ﬂow cytometry data, CD34 staining revealed that the
median number of microvessels in the BM was signiﬁ-
cantly reduced in the PT patients compared with that of
the GGF patients and the HDs (2 versus 4 versus 6 per
trabecular bone, respectively, P < .05) (Figure 3). More-
over, lower percentages of perivascular cells were
observed upon IHC staining for CD146 (2 versus 5 versus 6
per microvessel, P < .05) in the PT patients compared with
the GGF patients and HDs, respectively. In contrast, the
numbers of osteopontin-positive endosteal cells on the
line of the trabecular bone did not differ signiﬁcantly
among the PT and GGF patients and the HDs (15 versus 16
versus 18 per hpf, P > .05).ELISA Analysis of SDF-1 and VEGF in BM Plasma
To analyze the possible roles of MK-active factors in the
occurrence of PT, we measured the SDF-1 and VEGF activity
in BM plasma from the PT and GGF patients at 3 months after
allo-HSCT, as well as in the HDs. As shown in Figure 4, the
plasma SDF-1 activity in the GGF patients was signiﬁcantly
higher than that in the PT patients (3928 pg/mL versus 3163
pg/mL, P ¼ .0002) and HDs (3928 pg/mL versus 1668 pg/mL,
P < .0001). Moreover, the GGF patients exhibited a signiﬁ-
cantly elevated level of plasma VEGF compared with the PT
patients (123 pg/mL versus 56 pg/mL, P < .0001) and HDs
(123 pg/mL versus 90.6 pg/mL, P ¼ .03).
Risk Factors for PT
In the univariate logistic regression, underlying disease
type, history of GVHD, CMV infection after allo-HSCT, and BM
microenvironment elements (including BMECs and CD146þ
perivascular cells) were associated with PT (P < .10). In the
multivariate logistic regression analysis, BMECs (odds ratio
[OR], 171.57; 95% conﬁdence interval [CI], 6.51 to 4520; P ¼
.002) and CMV infection after allo-HSCT (OR, 4.35; 95% CI,
1.45 to 12.82; P ¼ .009) emerged as independent risk factors
for PT (Table 2).
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Figure 4. SDF-1 (A) and VEGF (B) levels in BM plasma measured using ELISA. The GGF patients exhibited signiﬁcantly elevated levels of plasma SDF-1 and VEGF
compared with those of the PT patients and HDs.
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In this prospective, nested case-control study, we
demonstrated for the ﬁrst time that the frequency of cellular
elements of the BM vascular microenvironment, including
BMECs and perivascular cells, and the levels of MK-active
factors in the BM plasma, including SDF-1 and VEGF, were
remarkably reduced in PT patients compared with in GGF
patients and HDs. Our results suggest that abnormalities in
the BM vascular microenvironment and MK-active factors
may contribute to the occurrence of PT after HSCT.
Severe delayed PT has been associated with life-
threatening complications and poor outcome after allo-
HSCT [27]. Impaired thrombopoiesis and increased PLT
turnover have been reported to be involved in the develop-
ment of PT after HSCT [28]. We previously found that PT after
allo-HSCTmay be related to a reduction in ploidy and defects
in the maturation of MKs [29]. In this regard, a shift in ploidyTable 2
Univariate and Multivariate Analysis of Risk Factors for PT
Factors Uni
Demographics
Gender, female versus male .4
Age, per decade .5
Disease characteristics
Diagnosis, MDS versus leukemia .0
Status, high-risk versus standard-risk .6
Pre-HSCT chemotherapy
Pre-HSCT cycles, per cycle .2
Transplantation characteristics
Donor match, ISD versus PMRD .7
Sex mismatch, FM versus FF versus MF versus MM .4
ABO mismatch, no versus minor versus major mismatch .2
Conditioning, modiﬁed BU/CY þ ATG versus other .5
Transplanted total MNCs, < 7.16  108/kg versus  7.16  108/kg .3
Transplanted CD34þ cells, < 2.46  106 kg versus  2.46  106/kg .2
Transplantation-related complications
History of GVHD, yes versus no .0
CMV infection after HSCT, yes versus no .0
Bone marrow microenvironment elements
Evaluated time, post-HSCT, d .4
*BMECs, < .10% versus  .10% <.0
xCD146þ perivascular cells, < .045% versus  .45% <.0
kOsteopontinþ endosteal cells, <13 per hpf versus 13 per hpf .5
PT indicates prolonged isolated thrombocytopenia; OR, odds ratio; CI, conﬁdence
transplantation; ISD, HLA-identical sibling donor; PMRD, HLAepartial matched rela
male to male; BU, busulfan; CY, cyclophosphamide; ATG, antithymocyte globulin;
alovirus; BMECs, bone marrow endothelial cells; hpf, high-power ﬁeld.
* BMECs separated into 2 risk groups according to the receiver operating charac
y P < .10 in univariate analysis.
z P < .05 in multivariate analysis.
x CD146þ perivascular cells were separated into 2 risk groups according to the R
k Osteopontinþ endosteal cells were separated into 2 risk groups according to thto the left may reﬂect selective damage to the more mature
MKs or the inhibition of the MKs maturation process. Poly-
ploid MKs localize to BMECs to mature and release PLTs. In a
reciprocal manner, the MKs, through platelet production and
release of key endothelial trophogens, such as SDF-1 and
VEGF, directly determine the integrity and viability of the BM
vascular microenvironment [13]. However, no previous
studies have focused on the characterization of the BM
microenvironment in PT patients after allo-HSCT.
The disruption of the vascular microenvironment or
interference with the motility of MKs has been shown
to inhibit thrombopoiesis under physiological conditions
and after myelosuppression in mice [30,31]. Alternatively,
several MK-active factors have been revealed to play
important roles in thrombopoiesis [14]. VEGF is a proan-
giogenic factor that interacts with its receptor (VEGF-R) on
BMECs to promote angiogenesis [13]. SDF-1 (also known asvariate Analysis P Value Multivariate Analysis*
OR 95% CI P Value
6
2
7y
6
9
9
4
3
6
6
3
5y
2y 4.35 1.45-12.82 .009z
2
001y 171.57 6.51-4520 .002z
001y
2
interval; MDS, myelodysplastic syndrome; HSCT, hematopoietic stem cell
ted donor; FM, female tomale; FF, female to female; MF, male to female; MM,
MNC, mononuclear cells; GVHD, graft-versus-host disease; CMV, cytomeg-
teristic (ROC) cutoff point with a sensitivity of 95% and speciﬁcity of 95%.
OC cutoff point with a sensitivity of 95% and speciﬁcity of 100%.
e ROC cutoff point with a sensitivity of 20% and speciﬁcity of 87.5%.
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studied and are well established to be essential for he-
matopoietic progenitor cell recruitment and angiogenesis
[32-34]. Moreover, SDF-1 augments the motility of MKs,
causing them to localize to the BMECs and thus support
thrombopoiesis [35]. The migration of CXCR4þ MKs through
BMECs in response to SDF-1 enhanced PLT production
in vitro [36]. Avecilla et al. [30] found that SDF-1 enhanced
the interaction between MK progenitors and BMECs in
Thpoe/e and Mple/e mice and facilitated thrombopoiesis.
Based on these studies [13,14,30,31,35,36], we speculate that
the elevated levels of SDF-1 and VEGF in GGF patients may
facilitate the localization of the immature MKs to a BMEC-
enriched vascular microenvironment, thereby promoting
differentiation, maturation, and PLT engraftment after HSCT.
Successful PLT reconstitution is dependent on both the
graft and the BM microenvironment. In previous studies, the
CD34þ cell dose in the graft has been reported to be positively
correlated with PLT engraftment after allo-HSCT [3,4]. In the
present study, although the infused total number of CD34þ
cells was equal, the number of CD34þ cells was signiﬁcantly
lower in allo-HSCT recipients with PT 3 months after allo-
HSCT. Moreover, BMB sections from the PT patients revealed
a relatively hypocellular marrow and remarkable reductions
in MKs and BM vascular microenvironmenteassociated
cellular elements compared with those of the GGF allo-HSCT
recipients. Considering the predominant role of the BM
vascular microenvironment in supporting thrombopoiesis
[14,30,31,35-37], it is reasonable that the impaired BM
vascular microenvironment and the associated MK-active
factors may have affected the thrombopoiesis of the suc-
cessfully engrafted donor CD34þ cells by disrupting the
interaction betweenMKs and BMECs, resulting in the delayed
PLT engraftment in the PT patients. Alternatively, the BMECs
and MK-active factors derived from the transplanted graft
mayalso playan important role in successful PLTengraftment
by inﬂuencing the recipients’ BM neovascularization
[32,34,38-40]. However, in the current descriptive study, the
BM microenvironment was evaluated at 3 months after allo-
HSCT. Thus, this scenario needs to be further validated by
analyzing the BM microenvironment components at early
time point after allo-HSCT (even before transplantation) in
the future. In contrastwith our previousﬁndings in secondary
PGFpatients [12], the levels of osteopontin-positive endosteal
cells were equivalent in the GGF and PT patients. These data
may explain why secondary PGF patients demonstrate more
severe pancytopenia than PT patients, indicating that
different degrees of BM microenvironment impairment may
have distinct effects on hematopoietic recovery after allo-
HSCT.
It is not known, however, what impairs the BM vascular
microenvironment and how this impairment drives the
occurrence of PT after allo-HSCT. CMV infection is 1 of the
most commonly reported factors in PT. In agreement with
previous studies [6,41-43], our ﬁndings indicated that more
PT patients had CMV infection soon after allo-HSCT, which is
1 of the independent risk factors for PT revealed by the
multivariate analysis. Several in vitro long-term BM culture
studies have previously reported that BM stromal cells can be
targets of CMV via direct cytotoxicity or immune-mediated
indirect destruction, and stromal CMV infection may nega-
tively affect the function of HSCs [41-43]. However, long-
term BM culture studies typically results in conﬂuent layers
of adherent cells composed of a heterogeneous population of
stromal cells [44]. In contrast, we investigated BMECs,perivascular cells, and endosteal cells by performing ﬂow
cytometry and histological analyses in situ because these
speciﬁc cellular elements represent the vascular and osteo-
blastic microenvironments, respectively [9-11,24]. Although
they require further validation in the aforementioned ele-
ments of the BM microenvironment, our data indicate that
CMV infection soon after allo-HSCTmay cause impairment of
the BM vascular microenvironment.
In conclusion, our data provide evidence that cellular el-
ements of the vascular microenvironment, including BMECs,
perivascular cells, and MK-active factors, are remarkably
reduced in PT patients, suggesting that an impaired BM
vascularmicroenvironmentmaycontribute to the occurrence
of PT after allo-HSCT. Although requiring further validation
with early time point analysis of the BM environment, our
data provide a rationale for better understanding of the cross-
talk between MKs and the BM vascular microenvironment in
PT patients may lead to an effective treatment that can
eventually improve PLT reconstitution after allo-HSCT.
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